Literature DB >> 9551996

Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member.

S Deaglio1, M Morra, R Mallone, C M Ausiello, E Prager, G Garbarino, U Dianzani, H Stockinger, F Malavasi.   

Abstract

Human CD38 is a cell surface molecule involved in the regulation of lymphocyte adhesion to endothelial cells. This suggests that HUVEC bear a ligand(s) for CD38 on the cell surface. By means of the mAb Moon-1, which specifically inhibits CD38-mediated cell adhesion, we have identified a trans-membrane 130-kDa molecule acting as a ligand for CD38. Here, we report that the molecule recognized by the Moon-1 mAb is CD31, a member of the Ig superfamily. This conclusion is based on 1) cross-inhibition assays between Moon-1 and reference anti-CD31 mAbs; 2) sequential immunoprecipitation experiments using Moon-1 and known anti-CD31 mAbs, and 3) reactivity of the Moon-1 mAb with CD31 transfectants. Further, CD31 and CD38 cognate interactions were found to modulate heterotypic adhesion as well as to implement cytoplasmic calcium fluxes identical to those obtained by means of agonistic anti-CD38 mAbs. Other effects tested included the synthesis of messages for a panel of cytokines, markedly increased upon receptor-ligand interactions. These results suggest that the interplay between CD38 and its ligand CD31 is an important step in the regulation of cell life and of the migration of leukocytes (and CD38+ cancer cells) through the endothelial cell wall.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551996

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  106 in total

1.  Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Authors:  P Bürgisser; C Hammann; D Kaufmann; M Battegay; O T Rutschmann
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  Differential modulation of cadherin-mediated cell-cell adhesion by platelet endothelial cell adhesion molecule-1 isoforms through activation of extracellular regulated kinases.

Authors:  N Sheibani; C M Sorenson; W A Frazier
Journal:  Mol Biol Cell       Date:  2000-08       Impact factor: 4.138

3.  Site-directed removal of N-glycosylation sites in BST-1/CD157: effects on molecular and functional heterogeneity.

Authors:  S Yamamoto-Katayama; A Sato; M Ariyoshi; M Suyama; K Ishihara; T Hirano; H Nakamura; K Morikawa; H Jingami
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

4.  Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils.

Authors:  Christopher J Kuckleburg; Sarah B Tilkens; Sentot Santoso; Peter J Newman
Journal:  J Immunol       Date:  2012-01-20       Impact factor: 5.422

5.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

6.  Soluble CD38 significantly prolongs the lifespan of memory B-cell responses.

Authors:  Xue Q Liu; Derek N J Hart; Gordon G MacPherson; Michael F Good; Michelle N Wykes
Journal:  Immunology       Date:  2008-09       Impact factor: 7.397

7.  Properties of human blood monocytes. II. Monocytes from healthy adults are highly heterogeneous within and among individuals.

Authors:  Dorothy Hudig; Kenneth W Hunter; W John Diamond; Doug Redelman
Journal:  Cytometry B Clin Cytom       Date:  2013-12-10       Impact factor: 3.058

Review 8.  PECAM-1: regulator of endothelial junctional integrity.

Authors:  Jamie R Privratsky; Peter J Newman
Journal:  Cell Tissue Res       Date:  2014-01-17       Impact factor: 5.249

9.  CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.

Authors:  Silvia Deaglio; Semra Aydin; Maurizia Mello Grand; Tiziana Vaisitti; Luciana Bergui; Giovanni D'Arena; Giovanna Chiorino; Fabio Malavasi
Journal:  Mol Med       Date:  2009-11-20       Impact factor: 6.354

Review 10.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.